Related references
Note: Only part of the references are listed.Genetic Polymorphism of XRCC1 Correlated with Response to Oxaliplatin-Based Chemotherapy in Advanced Colorectal Cancer
Hongying Lv et al.
PATHOLOGY & ONCOLOGY RESEARCH (2012)
Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis
Junshik Hong et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
ERCC1 and ERCC2 Polymorphisms Predict Clinical Outcomes of Oxaliplatin-Based Chemotherapies in Gastric and Colorectal Cancer: A Systemic Review and Meta-analysis
Ming Yin et al.
CLINICAL CANCER RESEARCH (2011)
Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy
Ming-Yii Huang et al.
PHARMACOGENETICS AND GENOMICS (2011)
Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer
Maria J. Lamas et al.
PHARMACOGENOMICS (2011)
The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer
Jun Liang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma
Yen-Chung Chen et al.
CANCER SCIENCE (2010)
Pharmacogenetics in chemotherapy of colorectal cancer
Lieke Henriette Tanja et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2009)
Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer
W. Chua et al.
BRITISH JOURNAL OF CANCER (2009)
Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy
L. Pare et al.
BRITISH JOURNAL OF CANCER (2008)
Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer
Eva Martinez-Balibrea et al.
EUROPEAN JOURNAL OF CANCER (2008)
Determination of ERCC2 Lys751 Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients:: relationships with treatment outcome
Valerie Le Morvan et al.
PHARMACOGENOMICS (2007)
Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population
Baorui Liu et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2007)
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy
Annamaria Ruzzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene?
Kwang Wook Suh et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy
S Gurubhagavatula et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
A de Gramont et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
XPD polymorphisms: effects on DNA repair proficiency
RM Lunn et al.
CARCINOGENESIS (2000)
Share Paper
